CD34 is expressed specifically on human hematopoietic stem cells and not on mature blood cells. CD34+ cells can reconstitute normal hematopoiesis of all cell lines, and to date it represents the only well defined human stem cell marker; therefore, it is a model for stem cell gene expression. Previous studies have defined the promoter for CD34, as well as identified a large fragment 3' of the CD34 gene containing an enhancer which appears to direct specific expression of GD34 in cell lines. The goal of this project is to further define and analyze the control elements of CD34, and to characterize those elements of the CD34 promoter and enhancer which can direct stem cell expression of heterologous genes. The characterization of these elements could lead to the development of new vectors for gene therapy, as well as new understanding of the factors regulating genes in stem cells. Therefore, the specific aims are to characterize and study the regulatory elements of CD34 in the following steps: (l) To isolate and characterize the precise genomic sequences comprising the functional and tissue specific elements of the CD34 3' enhancer; (2) To demonstrate that the same elements which control CD34 gene expression in cell lines regulate its expression in normal hematopoietic cells, demonstrating that these elements regulate CD34 expression in transgenic mice and in normal human CD34+ cells; (3) To isolate the minimal CD34 promoter/enhancer which will direct expression of a reporter gene in stem cells; and (4) To characterize the transcription factor(s) which interact with the CD34 3' enhancer elements defined in aims (l) and (2) to control the expression of CD34. These studies should lead to a better understanding of the regulation of stem cell genes, as well as the identification of the transcription factors which regulate them. In addition, these experiments shall also define the minimal regulatory elements necessary to direct stem cell expression of foreign genes, which should lead to new applications in gene therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK048660-01
Application #
2149064
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1994-09-30
Project End
1998-08-31
Budget Start
1994-09-30
Budget End
1995-08-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Koschmieder, Steffen; Gottgens, Berthold; Zhang, Pu et al. (2005) Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105:324-34
Huettner, Claudia S; Koschmieder, Steffen; Iwasaki, Hiromi et al. (2003) Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood 102:3363-70
Okuno, Yutaka; Huettner, Claudia S; Radomska, Hanna S et al. (2002) Distal elements are critical for human CD34 expression in vivo. Blood 100:4420-6
Radomska, Hanna S; Gonzalez, David A; Okuno, Yutaka et al. (2002) Transgenic targeting with regulatory elements of the human CD34 gene. Blood 100:4410-9
Radomska, H S; Satterthwaite, A B; Taranenko, N et al. (1999) A nuclear factor Y (NFY) site positively regulates the human CD34 stem cell gene. Blood 94:3772-80
Iwama, A; Zhang, P; Darlington, G J et al. (1998) Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha. Nucleic Acids Res 26:3034-43
Radomska, H S; Satterthwaite, A B; Burn, T C et al. (1998) Multiple control elements are required for expression of the human CD34 gene. Gene 222:305-18
Yamanaka, R; Kim, G D; Radomska, H S et al. (1997) CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing. Proc Natl Acad Sci U S A 94:6462-7
Tenen, D G; Hromas, R; Licht, J D et al. (1997) Transcription factors, normal myeloid development, and leukemia. Blood 90:489-519
Chen, H M; Zhang, P; Voso, M T et al. (1995) Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B. Blood 85:2918-28

Showing the most recent 10 out of 12 publications